Prof. HE Mingguang, Director of Research Centre for SHARP Vision (RCSV), Chair Professor of Experimental Ophthalmology and Henry G. Leong Professor in Elderly Vision Health, was interviewed by Wen Wei Po to discuss two ground-breaking studies he leads. Both projects, recognised as world-leading innovations, have secured multiple patents. Among his innovations is the AI-powered, portable retinal fundus camera designed for self-testing screening for diabetic eye. This device enables efficient, comprehensive and accurate screening without requiring trained technicians. It automatically targets the subject’s eyes to capture fundus images within one minute without pupil-dilation or fluorescein injection. After this, the device transmits the image to an AI system, which assesses the optic nerve, fundus in both eyes, and detects signs of glaucoma, diabetic retinopathy or cataract, without requiring interpretation from medical professionals. The research team has collaborated with OPTICAL 88 to install these devices in designated stores for public use. For myopia management, Prof. He’s team developed a non-invasive repeated low-level red-light (RLRL) therapy to reduce the progression of childhood myopia. The team has recently improved the treatment by reducing light intensity, shortening treatment duration and optimising the illumination system. The therapy can halt myopia progression and even reduce the degree of myopia. Research showed that individuals with high myopia have their prescription reduced from 500 to 450 degrees after the treatment. This advancement offers a breakthrough solution to manage the global rise of myopia among children. The two innovations underscore Prof. He’s commitment to transforming eye care through accessible, cutting-edge technologies. Online coverage: Wen Wei Po - https://polyu.me/4l5I8kX; https://polyu.me/4j89lSl; https://polyu.me/3XxeNpy
| Research Units | Research Centre for SHARP Vision |
|---|
